Cardiovascular diseases are the leading cause of death in worldwide countries and it is estimated that they will soon occupy the same status in developing countries.
The costs and social impacts of this global health problem are very high, which is why it is fundamental to promote and support a correct preventive path.
Nutrition and lifestyle are, in particular, the factors to which it is necessary to pay more attention in order to reduce the chances of cardiac problems occurring.
Phaax, continuously supports this need, aiming to raise awareness among Health Operators of the importance of prevention. With this in mind, Phaax’s commitment is to provide innovative product formulations with proven effectiveness, taking full advantage of the technological innovations available.
The activity of the company in the cardiometabolic field is mainly focused on the control of cholesterol and triglycerides in the blood, offering therapeutic solutions both in primary and secondary prevention of heart attack.
Our key therapeutic areas are:
- Cardiology/Vascular Diseases
- Infections and Infectious Diseases
Generic medicines (or: generics) are fully equivalent to the originator product in strength, route of administration, quality and performance characteristics, and intended use.
A generic drug must contain the same active ingredients as the original drug to be therapeutically equivalent and thus substitutable for the reference product. Generic medicines present the same quality and safety as the originator product. They are submitted to the same standards, which are enforced by the relevant regulatory authorities.
The mission of our generics business is to make healthcare more affordable and to improve access to important medicines through the provision of high-quality small-molecule generics to patients all around MENA region. Currently our products are under approval by regulatory agencies in around five countries and marketed through strategic partnerships and – in dedicated areas – through direct sales.